The utility of laboratory testing for pediatric patients undergoing isotretinoin treatment
© 2022 Wiley Periodicals LLC..
Isotretinoin, the most effective treatment for severe cystic acne, involves laboratory monitoring. In this retrospective case series of 130 pediatric patients taking isotretinoin, there were significant increases in cholesterol (143.9 mg/dl to 155.3 mg/dl), triglycerides (81.8 mg/dl to 115.2 mg/dl), and low-density lipoprotein (82.0 mg/dl to 98.1 mg/dl), and a decrease in high-density lipoprotein (50.0 mg/dl to 44.7 mg/dl) from baseline to follow-up (p < .05); there were no significant changes in liver enzymes. None of the patients had clinical sequelae (triglyceride-induced pancreatitis, retinoid-induced hepatotoxicity) related to their abnormal lab values. These findings question the utility of laboratory monitoring for prevention of severe clinical sequelae in pediatric patients, and suggest testing based on individualized risk factors may be more appropriate.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Pediatric dermatology - 39(2022), 5 vom: 08. Sept., Seite 731-733 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Parthasarathy, Varsha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
97C5T2UQ7J |
|---|
| Anmerkungen: |
Date Completed 11.10.2022 Date Revised 11.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/pde.15045 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342111280 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342111280 | ||
| 003 | DE-627 | ||
| 005 | 20231226013332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/pde.15045 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1140.xml |
| 035 | |a (DE-627)NLM342111280 | ||
| 035 | |a (NLM)35689471 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Parthasarathy, Varsha |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The utility of laboratory testing for pediatric patients undergoing isotretinoin treatment |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.10.2022 | ||
| 500 | |a Date Revised 11.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Wiley Periodicals LLC. | ||
| 520 | |a Isotretinoin, the most effective treatment for severe cystic acne, involves laboratory monitoring. In this retrospective case series of 130 pediatric patients taking isotretinoin, there were significant increases in cholesterol (143.9 mg/dl to 155.3 mg/dl), triglycerides (81.8 mg/dl to 115.2 mg/dl), and low-density lipoprotein (82.0 mg/dl to 98.1 mg/dl), and a decrease in high-density lipoprotein (50.0 mg/dl to 44.7 mg/dl) from baseline to follow-up (p < .05); there were no significant changes in liver enzymes. None of the patients had clinical sequelae (triglyceride-induced pancreatitis, retinoid-induced hepatotoxicity) related to their abnormal lab values. These findings question the utility of laboratory monitoring for prevention of severe clinical sequelae in pediatric patients, and suggest testing based on individualized risk factors may be more appropriate | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acne | |
| 650 | 4 | |a dermatology | |
| 650 | 4 | |a hepatotoxicity | |
| 650 | 4 | |a isotretinoin | |
| 650 | 4 | |a laboratory | |
| 650 | 4 | |a liver enzymes | |
| 650 | 4 | |a pancreatitis | |
| 650 | 4 | |a pediatrics | |
| 650 | 4 | |a triglycerides | |
| 650 | 7 | |a Lipoproteins, HDL |2 NLM | |
| 650 | 7 | |a Lipoproteins, LDL |2 NLM | |
| 650 | 7 | |a Triglycerides |2 NLM | |
| 650 | 7 | |a Cholesterol |2 NLM | |
| 650 | 7 | |a 97C5T2UQ7J |2 NLM | |
| 650 | 7 | |a Isotretinoin |2 NLM | |
| 650 | 7 | |a EH28UP18IF |2 NLM | |
| 700 | 1 | |a Shah, Nidhi |e verfasserin |4 aut | |
| 700 | 1 | |a Kirkorian, Anna Yasmine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric dermatology |d 1986 |g 39(2022), 5 vom: 08. Sept., Seite 731-733 |w (DE-627)NLM012965154 |x 1525-1470 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2022 |g number:5 |g day:08 |g month:09 |g pages:731-733 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/pde.15045 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2022 |e 5 |b 08 |c 09 |h 731-733 | ||